Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22802397 | 0.83 | RXRB (0.36) | KDM4EALDH1A1MEN1KMT2APOLB | |
| SCHEMBL26835893 | 0.78 | ALDH1A1 (0.42) | KDM4EHPGDHSD17B10ALDH1A1MEN1 | |
| SCHEMBL22802398 | 0.77 | KDM4E (0.39) | KDM4EHPGDHSD17B10ALDH1A1MEN1 | |
| SCHEMBL20699038 | 0.74 | HPGD (0.37) | KDM4EHPGDHSD17B10ALDH1A1MEN1 | |
| SCHEMBL19475186 | 0.74 | NLRP3 (0.47) | KDM4EHPGDHSD17B10ALDH1A1MEN1 | |
| SCHEMBL31397555 | 0.73 | MTNR1A (0.38) | AAK1BACE1BACE2USP30PRMT5 | |
| SCHEMBL21962078 | 0.72 | MTNR1A (0.45) | KDM4EHPGDHSD17B10ALDH1A1MEN1 | |
| SCHEMBL25067020 | 0.72 | NLRP3 (0.45) | KDM4EHPGDHSD17B10ALDH1A1MEN1 | |
| SCHEMBL24840121 | 0.71 | P2RX7 (0.37) | PARP1 | |
| SCHEMBL28831157 | 0.71 | MTNR1A (0.40) | AAK1USP30PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030879-B2 | Sulfonyl acetamides as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2024-07-09 | — | — | US | disclosed |
| US-11884645-B2 | Sulfonyl acetamides as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2024-01-30 | — | — | US | disclosed |
| US-11834433-B2 | Compounds | INFLAZOME LIMITED (IE) | 2023-12-05 | — | — | US | disclosed |
| US-11834433-B2 | Compounds | INFLAZOME LIMITED (IE) | 2023-12-05 | — | — | US | disclosed |
| US-11834433-B2 | Compounds | INFLAZOME LIMITED (IE) | 2023-12-05 | — | — | US | disclosed |
| US-11530200-B2 | Compounds | INFLAZOME LIMITED (IE) | 2022-12-20 | — | — | US | disclosed |
| US-11530200-B2 | Compounds | INFLAZOME LIMITED (IE) | 2022-12-20 | — | — | US | disclosed |
| US-20210047302-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2021-02-18 | — | — | US | disclosed |
| US-20210047302-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2021-02-18 | — | — | US | disclosed |
| US-20210040065-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2021-02-11 | — | — | US | disclosed |
| US-20210040065-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2021-02-11 | — | — | US | disclosed |
| US-20210002274-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2021-01-07 | — | — | US | disclosed |
| US-20210002274-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2021-01-07 | — | — | US | disclosed |
| US-20200399243-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-12-24 | — | — | US | disclosed |
| US-20200399243-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047302-A1 | NOVEL COMPOUNDS | NLRP3, NOD1, CBR3 | KDM4E 3268/4885HPGD 639/4885HSD17B10 828/4885 |
| US-20210040065-A1 | NOVEL COMPOUNDS | NLRP3, NOD1, NLRP1 | KDM4E 2406/4885HPGD 291/4885HSD17B10 317/4885 |
| US-12030879-B2 | Sulfonyl acetamides as NLRP3 inhibitors | NLRP3, NOD1, NLRP1 | KDM4E 2211/4885HPGD 1670/4885HSD17B10 967/4885 |
| US-20200399243-A1 | NOVEL COMPOUNDS | NLRP3, NOD1, NLRP1 | KDM4E 3031/4885HPGD 676/4885HSD17B10 695/4885 |
| US-11884645-B2 | Sulfonyl acetamides as NLRP3 inhibitors | NLRP3, NOD1, ABCC5 | KDM4E 2934/4885HPGD 1317/4885HSD17B10 699/4885 |
| US-11834433-B2 | Compounds | NLRP3, NOD1, PYCARD | KDM4E 1949/4885HPGD 275/4885HSD17B10 313/4885 |
| US-20210002274-A1 | NOVEL COMPOUNDS | NLRP3, NOD1, NLRP1 | KDM4E 2915/4885HPGD 764/4885HSD17B10 975/4885 |
| US-11530200-B2 | Compounds | NLRP3, NOD1, NLRP1 | KDM4E 3491/4885HPGD 467/4885HSD17B10 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.